Table 1.

Clinical characteristics of study cohorts.

Parameter	Chronic HCV (no therapy)	Chronic HCV (sofosbuvir-treated)	Healthy
Time point		Baseline
Number of subjects (n)	69	7	90
Number of HLA-A2 positive patients	61	7	67
Male sex – no. (%)	36 (52)	3 (43)	N/A
Age (years)
Median	49	57	N/A
Range	22–80	53–67	N/A
HCV RNA – (IU/ml)
Median	1.2 × 106	730,000	N/A
Range	8.6 × 104–9.8 × 106	1.8 × 105–1.1 × 107	N/A
≥8 × 105 IU/ml – no./total no. (%)	39/63 (62)	3/7 (43)	N/A
Unknown	6/69 (9)	N/A	N/A
Undetectable	6/69 (9)	N/A	N/A
Alanine aminotransferase – (U/l)
Median	71.5	67	N/A
Range	10–311	28–224	N/A
Above median – no./total no. (%)	34/68 (50)	3/7 (43)	N/A
Unknown	1/69 (1.5)	N/A	N/A
Aspartate aminotransferase – (U/l)
Median	54.5	54	N/A
Range	22–279	27–118	N/A
Above median – no./total no. (%)	34/68 (50)	3/7 (43)	N/A
Unknown	1/69 (1.5)	N/A	N/A
HCV genotype – no. (%)
1	50 (82)	0 (0)	N/A
2	2 (3)	1 (14)	N/A
3	9 (15)	5 (72)	N/A
5	0 (0)	1 (14)	N/A
Not determined	8 (12)	0 (0)	N/A

N/A, not applicable.